Overview
Vilon is a synthetic dipeptide (Lys-Glu, or KE) originally developed by the St. Petersburg Institute of Bioregulation and Gerontology as a bioregulator targeting the vascular system and connective tissue. It belongs to a class of peptide compounds known as bioregulators—short amino acid chains designed to modulate cellular function and gene expression at the molecular level.
The compound has been studied primarily in Russian clinical settings for its geroprotective properties, with research focusing on vascular health, immune function, and age-related cellular decline. Unlike many pharmaceutical compounds, Vilon works not through a single target receptor but rather as a gene expression modulator that influences how cells age and respond to stress.
This article provides a comprehensive, evidence-based review of Vilon's mechanisms, research findings, dosing protocols, and safety profile. It is intended for educational purposes and should not be construed as medical advice. Consult a qualified healthcare provider before using any research compound.
How Vilon Works: Mechanism of Action
Vilon operates through a sophisticated molecular mechanism that sets it apart from conventional pharmaceuticals. The compound acts as a short peptide bioregulator capable of penetrating cell nuclei and interacting directly with chromatin—the complex of DNA and proteins that controls gene expression.
Cellular Penetration and Nuclear Activity
Once administered, Vilon crosses cell membranes and reaches the nucleus, where it modulates gene expression in endothelial cells (which line blood vessels) and smooth muscle cells. This direct interaction with chromatin allows it to influence which genes are activated or suppressed, fundamentally altering how cells function and age.
Molecular Effects
The compound has been shown to:
- Normalize vascular wall components: Restores the structural integrity of blood vessel walls by regulating the synthesis of proteins that make up vessel tissue
- Upregulate antioxidant defenses: Activates genes that produce antioxidant enzymes, helping cells resist oxidative damage
- Modulate cell proliferation and apoptosis: Influences genes controlling whether cells divide or undergo programmed death, both critical to healthy aging
- Restore neurohumoral regulation: Helps normalize the nervous system's and hormonal system's control over blood vessel function
Gene Expression Changes
Research has documented specific changes in gene expression following Vilon administration. In aged human mesenchymal stem cells, Vilon increased SIRT1 gene expression 6-fold and protein synthesis 8.2-fold—effects associated with cellular longevity and stress resistance. Simultaneously, it reduced PARP1 and PARP2 expression, genes associated with cellular aging and stress.
Evidence by Health Goal
Muscle Growth
Evidence Tier: 1 (Minimal Evidence)
Vilon has not been studied for muscle growth in humans or animals. All available research focuses on immune function, aging, and gene expression in non-muscle tissues. No efficacy for muscle growth has been demonstrated.
Injury Recovery
Evidence Tier: 2 (Plausible but Unproven in Humans)
Vilon shows promising effects on tissue regeneration in animal models, though human efficacy remains unproven.
In aged rat spleen tissue (2 years old), Vilon at 20 ng/ml induced morphologic stability and activated tissue regeneration and cell functional activity. The effect was significantly stronger in aged tissue than younger tissue, suggesting a geroprotective mechanism.
In a rat model of cirrhotic liver disease (induced by CCl₄), Vilon at 1.7 μg/kg administered over 5 days elevated glucose-6-phosphatase activity that had been reduced 1.2-fold by cirrhosis, suggesting partial restoration of liver function.
However, these findings come exclusively from animal studies. Human clinical trials demonstrating efficacy for injury recovery have not been conducted.
Anti-Inflammation
Evidence Tier: 2 (Plausible but Unproven in Humans)
Vilon demonstrates anti-inflammatory effects in animal and cell culture models, with no human clinical trials to confirm efficacy.
In rats with chronic renal failure, Vilon decreased serum TGF-beta1 concentration and microvessel permeability at two months post-treatment. TGF-beta1 is a key inflammatory signaling molecule elevated in aging and disease.
In mouse splenocytes (immune cells) studied in-vitro, Vilon activated IL-2 mRNA synthesis—a process typically requiring immune stimulation—in a dose- and time-dependent manner. This suggests the peptide can activate immune signaling even without external triggers.
Cognition
Evidence Tier: 2 (Plausible but Unproven in Humans)
Vilon shows plausible mechanisms for supporting cognition through effects on immune cell differentiation and stress resilience, but human trials are absent.
The peptide stimulated differentiation of pineal gland immune cell precursors into T-helper and cytotoxic T lymphocytes in organotypic culture, suggesting it can enhance immune surveillance in the central nervous system.
In emotionally stressed rats, Vilon administration reduced the number of c-Fos-positive neurons in the paraventricular hypothalamus (a brain region governing stress response) and increased emotional stress resistance as measured by open-field behavioral tests.
Mood & Stress
Evidence Tier: 2 (Plausible but Unproven in Humans)
Vilon demonstrates stress-buffering effects in rodent models, though human evidence is completely absent.
In rats exposed to mild stress, intranasal Vilon reduced IL-2-positive cells in hypothalamic structures within 2 hours, with sustained effects depending on adaptation status.
In male Wistar rats, Vilon administration increased emotional stress resistance by behavioral measures and prevented stress-induced adrenal hypertrophy and thymus involution—common markers of chronic stress pathology in rodents.
Longevity
Evidence Tier: 2 (Plausible but Unproven in Humans)
Vilon demonstrates geroprotective mechanisms supported by consistent animal and mechanistic studies, though direct longevity effects in humans remain unproven.
In humans with type 1 diabetes, Vilon increased antithrombin III and protein C (natural anticoagulants), stimulated fibrinolysis, normalized T-cell and B-cell populations, and reduced insulin requirements. These metabolic and immune improvements suggest a geroprotective effect, though lifespan was not measured.
In aged human mesenchymal stem cells cultured in-vitro, Vilon increased SIRT1 gene expression 6-fold and protein synthesis 8.2-fold—SIRT1 being a key "longevity gene" associated with extended healthspan in multiple organisms. The peptide also reduced PARP1 expression 2.1-fold and protein synthesis 5.3-fold, along with PARP2 expression 2.1-fold and protein synthesis 4.7-fold.
Immune Support
Evidence Tier: 2 (Plausible but Unproven in Humans)
Vilon shows consistent immunomodulatory effects in animal models and one small human trial, though independent human replication is lacking.
In diabetic patients treated with Vilon, the peptide normalized T-helper cells, T-dependent NK cells, B-lymphocytes, and IgA levels while reducing insulin requirements and improving anticoagulant markers (antithrombin III and protein C), suggesting broad immune stabilization and metabolic benefit.
In aged rat spleens cultured organotypically at 20 ng/ml, Vilon induced morphologic stability and activated regeneration and functional activity, with stronger effects in old versus young tissue.
Energy & Cellular Function
Evidence Tier: 2 (Plausible but Unproven in Humans)
Vilon shows plausible mechanisms for supporting cellular energy through mitochondrial optimization, though human efficacy is unproven.
Vilon inhibited reactive oxygen species generation in mitochondria in fruit flies (Drosophila melanogaster) with sex- and age-related variations, suggesting it may protect mitochondrial function from oxidative damage.
In human thymic cells experiencing senescence cultured in-vitro, Vilon increased mitochondrial staining (MitoTracker Red) by 1.5-fold, indicating enhanced mitochondrial content or function.
Skin & Hair
Evidence Tier: 1 (Minimal Evidence)
Vilon shows promise in cell culture for promoting collagen expression, but human clinical trials are absent.
In aged human skin fibroblasts (primary cell culture), Vilon increased collagen type I expression area by 83% compared to controls and increased sirtuin-6 expression by 2.6-fold. Sirtuin-6 is a protein associated with cellular longevity and DNA repair. However, these are cell culture findings with no human skin efficacy data.
Gut Health
Evidence Tier: 2 (Plausible but Unproven in Humans)
Vilon shows consistent positive effects on digestive enzyme activity in aged rats, but human efficacy remains completely unproven.
In aged rats (11 months old) given oral Vilon for one month, the peptide significantly increased activity of membrane enzymes maltase and alkaline phosphatase in the small intestine epithelial layer. It also increased cytosolic glycyl-L-leucine dipeptidase activity in stromal and seromuscular layers compared to control rats.
Heart Health
Evidence Tier: 2 (Plausible but Unproven in Humans)
Vilon shows plausible cardiovascular mechanisms in animal studies, but human trials are absent.
In rats with chronic renal failure, Vilon significantly decreased serum TGF-β1 concentration and mesenteric microvessel permeability at two months post-treatment, suggesting vascular protective effects.
In mouse heart tissue, Vilon altered expression of 36 genes with maximal activation of 6.13-fold and inhibition up to 2.79-fold, indicating broad effects on cardiac gene expression.
Liver Health
Evidence Tier: 2 (Plausible but Unproven in Humans)
Vilon shows potential benefits for liver function in animal models of cirrhosis, with no human trials conducted.
In cirrhotic rats, Vilon restored glucose-6-phosphatase activity reduced by cirrhosis and increased total protein content in hepatocytes by 4.7-fold compared to untreated cirrhotic controls, suggesting restoration of hepatic metabolic capacity.
Hormonal Balance
Evidence Tier: 3 (Probable Efficacy Based on Limited Human Data)
Vilon demonstrates effects on hormonal regulation in two small human trials, making this one of the best-supported health goals—though evidence remains limited by small sample sizes and lack of independent replication.
In type 1 diabetic patients treated with Vilon, insulin dose requirements decreased, and natural anticoagulants (antithrombin III, protein C) increased over the treatment course. These changes suggest improved neuroendocrine regulation and metabolic control.
In aged male rats with induced hypogonadism, a 50 μg dose of Vilon significantly activated sexual function parameters, decreased prolactin levels (which inhibits sexual function), and increased LH and ACTH—hormones critical to sexual and neuroendocrine function.
Sexual Health
Evidence Tier: 1 (Minimal Evidence)
Vilon shows potential to activate sexual function in aged male rats through neuroendocrine modulation, but human efficacy is completely unproven.
A single small animal study found that Vilon at 50 μg per rat activated sexual function in aged, hypogonadal male rats and significantly decreased blood prolactin content. No human trials exist.
Athletic Performance
Evidence Tier: 2 (Plausible but Unproven in Humans)
Vilon increased physical activity and endurance in aging mice, though no human studies demonstrate efficacy for athletic performance.
In female CBA mice aged 6 months or older, Vilon increased physical activity and endurance (specific magnitude not quantified in available literature) and decreased body temperature. This single animal study lacks independent replication in humans.